Investing in start-ups
Biocodex has invested in start-ups since 2016 and become a key player in the French biotech ecosystem. We focus mainly on companies developing innovative therapeutics with probiotics or microbial strains that are beneficial to health. With its long-term approach and industrial expertise, Biocodex is recognized as a valuable partner by CEOs, project owners and traditional investors, such as fund managers. Biocodex is always looking to support new meaningful projects.
Biocodex invests in MaaT Pharma
Biocodex has invested in MaaT Pharma since 2016. MaaT Pharma’s research exploits the potential of fecal microbiota transplantation (FMT) as a therapeutic option, accelerating innovation in microbiota therapy. Biocodex brings more than 60 years of industrial expertise in the strain cultures, lyophilization and oral treatment. MaaT Pharma’s pipeline is focused on the use of FMT as therapeutics on the Graft-versus-host disease (GvHD) and acute myeloid leukemia (AML) patients. MaaT Pharma has also developed Maat Microbiome Restoration Biotherapeutics (MMRB) technology focusing on data collection and analysis (the GutPrint® platform), along with a current good manufacturing practice (cGMP) facility.
Biocodex invests in Exeliom Biosciences
Biocodex has invested in Exeliom Biosciences since 2018. This company’s mission is to develop a new class of medicines, Live Biotherapeutics, based on the growing understanding of the central role of the microbiota in the immune system. Exeliom Biosciences has developed a mono-strain approach using Faecalibacterium prausnitzii, which it believes could significantly improve the treatment of inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis.
Biocodex invests in TargEDys
In 2019, Biocodex acquired a stake in TargEDys, a start-up aiming to act on metabolism balance. Among the company’s innovations, Probiosatys™ with a unique strain Hafnia alvei 4597. This technology is available to consumers through Biocodex’s Symbiosys® Satylia® product.
Biocodex invests in Kinnov Therapeutics
Biocodex has invested in Kinnov Therapeutics since 2018. Kinnov Therapeutics concentrates its research on the combination of cyproheptadine and prazosin, two molecules that work in synergy to treat addictions.
Kinnov Therapeutics is conducting a Phase II clinical trial to confirm the efficacy of combined cyproheptadine and prazosin in the treatment of alcohol addiction, a field lacking in medical solutions. This project has received funding from the European Union’s Horizon 2020 Research and Innovation program.
Want to know more?
Partnering with Biocodex means cooperating in investments that create successful synergies. Biocodex aims to continue its development by focusing on our three pillars: the Microbiota Mission, Orphan drugs and Women's health. Biocodex business development team is constantly seeking for new opportunities.